archive-com.com » COM » H » HBMPARTNERS.COM

Total: 38

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • HBM Partners AG - Home
    HBM Partners advises HBM Healthcare Investments and healthcare related public and private equity funds Investment Products HBM Partners advises HBM Healthcare Investments and healthcare related public and private equity funds Portfolio HBM Partners actively supports a portfolio of some 40 growth companies focusing on value creation from innovative technologies and novel products Portfolio HBM Partners actively supports a portfolio of some 40 growth companies focusing on value creation from innovative

    Original URL path: http://www.hbmpartners.com/en/index.php (2016-04-25)
    Open archived version from archive


  • HBM Partners AG - Contact
    enter the characters you see on the screen into the box reset submit mandatory Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year

    Original URL path: http://www.hbmpartners.com/en/kontakt/index.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Sitemap
    Approval Report Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016

    Original URL path: http://www.hbmpartners.com/en/sitemap/index.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Welcome to HBM Partners
    experienced professionals to source analyze execute and exit investments in the pharma biotech medical devices and diagnostics industries HBM Partners has been an active contributor to value creation in its portfolio companies generating over 40 trade sales and IPOs since inception FINMA Authorization As an independent supervisory authority FINMA acts to protect the interests of creditors investors and insured persons and to ensure the proper functioning of the financial markets FINMA approves and supervises the financial market participants Following the revision of the Swiss collective investment schemes act HBM Partners applied for an asset manager and representative license and has become subject to supervision by FINMA in February 2015 The authorization as asset manager also includes the license as distributor As such it is in compliance with all regulatory and legal requirements placed to manage and distribute collective investment schemes in Switzerland Link FINMA Website Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3

    Original URL path: http://www.hbmpartners.com/en/unternehmen/profil.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Healthcare Investments
    Healthcare Investments an interesting alternative to investing in big pharma and biotech companies HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange ticker HBMN Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50

    Original URL path: http://www.hbmpartners.com/en/investment-products/hbm-healthcare-investments.php?navid=675409675409 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Current Private Portfolio
    PAH and lymphedema Ellipse Technologies USA Adjustable orthopedic implants Company Website www ellipse tech com HBM contact Dr Thomas Thaler Company status private Ellipse Technologies designs develops and commercializes non invasively adjustable remote controlled implants for a broad spectrum of spinal and othopedic applications Ellipse products aid to restore proper anatomic position and aligemnt of the spine and correct limb length discrepancies Gynesonics USA Women s Health Company Website www gynesonics com HBM contact Dr Chandra Leo Company status private Gynesonics focuses on the incision less therapy of symptomatic uterine fibroids the most common benign tumors in women Gynesonics has developed VizAblate a transcervical ultrasound guided ablation system which has a CE Mark in the European Union i Optics Netherlands Diagnostics ophthalmology Company Website www i optics com HBM contact Dr Chandra Leo Company status private he EasyScan scanning laser ophthalmoscope offers a dilation free 3 minute retinal exam for the early detection of diseases such as diabetic retinopathy The Cassini color LED topographer provides a highly precise 3 dimensional map of the cornea supporting e g cataract surgery planning and determination of IOL implants Iconic Therapeutics Drug development ophthalmology Company Website www iconictherapeutics com HBM contact Dr Priyanka Belawat Dr Matthias Fehr Company status private Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines for serious diseases The company s expertise in the role of Tissue Factor TF in angiogenesis inflammation and metastasis has allowed us to develop a unique therapeutic approach to retinal disease and cancer Interventional Spine USA Percutaneous spine implants Company Website www i spineinc com HBM contact Dr Thomas Thaler Company status private Interventional Spine designs develops and markets patented implantable devices for the spine that can be deployed via percutaneous techniques Kolltan Pharmaceuticals USA Drug development oncology Company Website www kolltan com HBM contact Axel Bolte MBA Company status private Kolltan Pharmaceuticals Inc is developing novel monoclonal antibody drugs targeting receptor tyrosine kinases RTKs Lipid Therapeutics Drug development inflammation Company Website lipid therapeutics com HBM contact Dr Alexander Asam Company status private Lipid Therapeutics GmbH is developing novel therapies for inflammatory diseases of the digestive system The company s current focus is to develop LT 02 a delayed release of Phosphatidylcholine for the treatment of Ulcerative colitis LT 02 is currently in PhIII clinical development MiCardia Corporation USA Heart valve implants Company Website www micardia com HBM contact Dr Thomas Thaler Company status private MiCardia is marketing its enCorSQ Mitral Valve Repair System in the Europe The enCorSQ device allows the surgeon to address any recurrent MR or coaptation correction real time off pump on a beating heart days or months after the surgical implant Nabriva Austria Drug development antibacterials Company Website www nabriva com HBM contact Axel Bolte MBA Company status public Nabriva Therapeutics is developing pleuromutilin antibiotics a new class of antibacterial compounds for the treatment of serious infections in humans caused by multi drug resistant pathogens ObsEva Women s Health Company Website www obseva

    Original URL path: http://www.hbmpartners.com/en/portfolio/current-private-portfolio.php?navid=837134837134 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    1 2016 NUVASIVE to aquire Ellipse Technologies 147 KB 6 1 2016 Vascular Dynamics MobiusHD System Receives CE Mark for the Treatment of Resistant Hypertension 117 KB 6 1 2016 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/news.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Industry Reports
    A Report 2016 Pharma Biotech MA Transactions 2005 2015 Excel Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for

    Original URL path: http://www.hbmpartners.com/en/industry-reports/pharma-biotech-report.php (2016-04-25)
    Open archived version from archive



  •